Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Shares Outstanding (Weighted Average) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 228.95% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 228.95% year-over-year, with the annual reading at $1.3 million for FY2025, 228.95% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.3 million at bioAffinity Technologies, up from $804604.0 in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $28.2 million in Q2 2025, with the low at $409937.0 in Q4 2024.
  • Average Shares Outstanding (Weighted Average) over 4 years is $7.3 million, with a median of $4.6 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 95.31% in 2024, then soared 228.95% in 2025.
  • Over 4 years, Shares Outstanding (Weighted Average) stood at $4.6 million in 2022, then soared by 88.12% to $8.7 million in 2023, then crashed by 95.31% to $409937.0 in 2024, then skyrocketed by 228.95% to $1.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $1.3 million, $804604.0, and $28.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.